04 March 2015

NICE, Level 1a, City Tower, Piccadilly Plaza, Manchester

The meeting will start promptly at 10:00 and is expected to finish at approximately 15:00

Please note that this agenda is subject to change prior to the meeting.

Final Agenda

  1. Welcome and introduction to format of meeting
  2. Apologies
  3. Any other business
  4. Minutes from the last Committee meeting held on 3 February 2015.
  5. Appraisal of Daclatasvir for treating chronic hepatitis C
    5.1. Declarations of interest - Part 1 only (open session)
    5.2. Introduction by the Chair, Professor Gary McVeigh - Part 1 only (open session)
    5.3. Presentation by the lead team -Part 1 AND part 2 (open and closed session)
    5.4. Agreement on the content of the Final Appraisal Determination (FAD) - Part 2 only (closed session)

Date, time and venue of next meeting:

Next Technology Appraisal (Committee D) Meeting: Wednesday 1 April 2015 10:00am, NICE, Level 1, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

Please note all timings are approximate.


To print the agenda, please right click and select 'Print' from the menu


To register

You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.

The closing date for registration is 18 February 2015. Please note that it may not be possible to accept late registration requests

Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Lee Berry

Please note that registrants wishing to conduct a research study on the committee meeting and/or NICE processes will require prior permission and should contact NICE Enquiry Handling by email nice@nice.org.uk further information about conducting research is also available in our Common Questions and Answers about meetings in public document


Registration period: 04 to 18 February 2015
Registration is closed.